中生方政NBF品牌怎么样 申请店铺

我要投票 中生方政NBF在医疗器械行业中的票数:6 更新时间:2024-11-22
中生方政NBF是哪个国家的品牌?「中生方政NBF」是 中生方政生物技术股份有限公司 旗下著名品牌。该品牌发源于江苏省泰州市,由创始人郭光华在2009-09-22期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
中生方政NBF怎么样

中生方政生物技术股份有限公司,成立于2009年,是一家集诊断试剂、生物医药、预防性疫苗及仪器设备的研发和生产为一体的生物医药技术企业。占地面积近55000平方米,建筑面积25700 平方米。研发总部设立在美国,主要从事具有国际前沿技术水平的体外诊断试剂的开发和研制。已建成核酸分子诊断试剂生产车间、金标车间、酶联免疫诊断试剂生产车间、中试(设备)车间、动力中心、动物实验楼、综合楼(研发中心)等标准化GMP生产车间及现代化办公配套设施,现已完成规模化产业基地的建设,形成了年产分子诊断试剂1000万人份和分子检测设备1000台的生产能力。

中生方政长期专注于临床分子诊断技术的开发。在国内IVD行业,中生方政是为数不多拥6项以上注册文号的生产企业,实现了产品价格多层次化,产品结构梯队化,可以满足不同客户的检测需求和价格承受能力,具有较宽的市场辐射面,为市场纵深开发打下了良好基础。

作为前沿技术创新主导型高科技企业,公司依托自主研发及联合开发等多种方式,创建了成熟稳定的新型核酸检测技术平台,并已先期开发出人乳头瘤病毒(HPV)临床检测试剂,成为国内首个利用恒温技术检测HPV病毒的产品。目前公司已获得国家食品药品监督总局颁发的15种型别人乳头瘤病毒和16/18型人乳头瘤病毒核酸检测试剂盒(恒温扩增-荧光法)、人乳头瘤病毒(HPV)基因分型检测试剂盒(恒温扩增-荧光法)、人乳头瘤病毒(HPV)核酸检测试剂盒(恒温扩增-荧光法)等产品注册证书。同时,公司还开发出配套的恒温荧光检测设备。依托于该技术平台,公司正在努力拓展产品线,逐步推进试剂和仪器的“系列化”、“一体化”发展目标。

中生方政将本着“用心、专注、创新、服务”的企业理念和“成为国内在体外诊断试剂产业领域最具创新研发能力的优秀产品与服务供应商”的发展愿景,“资本加创新”双轮驱动的发展战略,以及“质量第一 追求卓越”的管理理念,愿同社会各界合作共赢,回馈股东、客户和员工,进而为推动我国医学检验产业及健康医疗事业的发展做出新的贡献。


Zhongsheng Fangzheng Biotechnology Co., Ltd., founded in 2009, is a biomedical technology enterprise integrating research and development and production of diagnostic reagents, biomedicine, preventive vaccines and equipment. It covers an area of nearly 55000 square meters and a building area of 25700 square meters. R & D headquarters is established in the United States, mainly engaged in the development and development of in vitro diagnostic reagents with international cutting-edge technology level. Standardized GMP production workshops and modern office facilities have been built, such as nucleic acid molecular diagnostic reagent production workshop, gold standard workshop, enzyme-linked immunodiagnostic reagent production workshop, pilot test (equipment) workshop, power center, animal laboratory building, comprehensive building (R & D center). The construction of large-scale industrial base has been completed, with an annual output of 10 million people and molecules of molecular diagnostic reagents Production capacity of 1000 testing equipment. Zhongsheng Fangzheng has long focused on the development of clinical molecular diagnosis technology. In the domestic IVD industry, Zhongsheng Fangzheng is one of the few manufacturers with more than 6 registered numbers. It has realized multi-level product price and echelon product structure, which can meet the testing needs and price tolerance of different customers. It has a wide market radiation and lays a good foundation for in-depth market development. As a leading high-tech enterprise of cutting-edge technology innovation, the company has established a mature and stable new nucleic acid detection technology platform relying on independent research and development and joint development, and has developed the clinical detection reagent of human papillomavirus (HPV) in advance, becoming the first domestic product using constant temperature technology to detect HPV virus. At present, the company has obtained product registration certificates issued by the State Food and drug administration, such as 15 types of HPV and 16 / 18 HPV nucleic acid detection kits (constant temperature amplification fluorescence method), HPV gene typing detection kits (constant temperature amplification fluorescence method), HPV nucleic acid detection kits (constant temperature amplification fluorescence method), etc Book. At the same time, the company also developed a complete set of constant temperature fluorescence detection equipment. Relying on this technology platform, the company is striving to expand its product line and gradually promote the development goals of "serialization" and "integration" of reagents and instruments. Zhongsheng Fangzheng is willing to cooperate with all walks of life for win-win cooperation and feedback with the corporate philosophy of "heart, focus, innovation and service", the development vision of "becoming the best product and service provider with the most innovative R & D ability in the field of in vitro diagnostic reagent industry in China", the development strategy of "capital plus innovation" driven by two wheels, and the management concept of "quality first pursuit of excellence" Shareholders, customers and employees will make new contributions to the development of China's medical testing industry and health care industry.

本文链接: https://brand.waitui.com/2c7dece2d.html 联系电话:052380766900

千城特选小程序码

7×24h 快讯

国家数据局:优化网络计费方式,降低东西部数据传输成本,促进东部中高时延业务向西部转移

36氪获悉,国家数据局向社会公开征求《国家数据基础设施建设指引(征求意见稿)》意见。其中提到,推进东中西部算力协同。加强新兴网络技术创新应用,优化网络计费方式,降低东西部数据传输成本,促进东部中高时延业务向西部转移。构建算力多级调度策略引擎,实现跨平台、跨层级、跨区域的算力资源混合部署和统一调度,促进算力资源高效对接,提升数据汇聚、处理、流通、交易效率。推动国家枢纽节点和需求地之间400G/800G高带宽全光连接,引导电信运营商提升“公共传输通道”效能,推进算网深度融合。

25分钟前

国家数据局:推动实现“瓦特”产业向“比特”产业转化,不断壮大数算产业生态体系

36氪获悉,国家数据局向社会公开征求《国家数据基础设施建设指引(征求意见稿)》意见。其中提到,推进算力与数据、算法融合创新。推动实现“瓦特”产业向“比特”产业转化,不断壮大数算产业生态体系,助力打造具有国际竞争力的数字产业集群。推动行业数据和算力协同,实现数据可信流通,提升数据处理能力和治理水平。建立健全算法开发利用机制,积极开展大模型创新算法及关键技术研究,提升数据分析能力,降低大模型计算的算力消耗水平。

25分钟前

国家数据局:建立健全数据基础制度体系,加快出台数据产权、流通交易、收益分配、安全治理等政策文件

36氪获悉,国家数据局向社会公开征求《国家数据基础设施建设指引(征求意见稿)》意见。其中提到,健全政策保障体系。建立健全数据基础制度体系,加快出台数据产权、流通交易、收益分配、安全治理等政策文件。在新型基础设施规划安排下,研究制定国家数据基础设施建设规划。加大中央投资对国家数据基础设施建设的支持力度。各地区、各部门要在数据基础设施规划布局、资金安排、课题研究方面给予重点支持。积极引导社会资本力量参与国家数据基础设施建设。

25分钟前

游戏股异动拉升,富春股份直线涨停

36氪获悉,截至发稿,游戏股异动拉升,富春股份直线涨停,盛天网络、星辉娱乐、冰川网络、姚记科技、大晟文化等纷纷走强。

25分钟前

腾讯出售超4亿美元Reddit股票

社交媒体公司Reddit股价在周四盘后下跌7.29%,此前腾讯披露称该公司出售了对Reddit的大量持股。根据提交给美国证券交易委员会(SEC)的文件,腾讯11月19日以平均每股133.76美元的价格出售了65.50万股Reddit股票,在11月14日至11月18日期间以平均每股约129.38美元的价格出售了88.26万股,在11月11日至13日以平均每股132.19美元的价格出售了近150万股。在总计价值超4亿美元的抛售后,腾讯对Reddit的持股减至775万股。(界面)

25分钟前

本页详细列出关于WEGO威高的品牌信息,含品牌所属公司介绍,WEGO威高所处行业的品牌地位及优势。
咨询